Sökning: WFRF:(Roman R)
> (2000-2004) >
Impact of age on le...
Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study)
-
Gerdts, E. (författare)
-
Roman, M. J. (författare)
-
Palmieri, V. (författare)
-
visa fler...
-
Wachtell, K. (författare)
-
Smith, G. (författare)
-
Nieminen, M. S. (författare)
-
- Dahlöf, Björn, 1953 (författare)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
Devereux, R. B. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2004
- 2004
- Engelska.
-
Ingår i: J Hum Hypertens. - 0950-9240. ; 18:6, s. 417-22
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- To assess the influence of age on changes in left ventricular (LV) mass and geometry during antihypertensive treatment, we related age to clinical and echocardiographic findings before and after 4 years of antihypertensive treatment in a subset of 560 hypertensive patients without known concurrent disease in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which randomized patients to blinded losartan- or atenolol-based treatment. Patients >/=65 years (older group) included more women and patients with isolated systolic hypertension or albuminuria (all P<0.05). Compared to patients <65 years, older patients had higher pulse pressure, LV mass, and prevalence of concentric hypertrophy at baseline (78 vs 69 mmHg, 234 vs 224 g, and 28 vs 16%, respectively, all P<0.01), while the mean blood pressure did not differ. Over 4 years, reductions in LV mass and the mean blood pressure were similar in both groups, but older patients more often had residual hypertrophy (31 vs 15%, P<0.001) with a preponderance of eccentric geometry. In multivariate analysis of 4-year change in LV mass controlling for baseline mass, larger hypertrophy reduction was associated with losartan treatment, while age, gender, body mass index, and 4-year change in pulse pressure and albuminuria did not enter (Multiple R (2)=0.40, P<0.001). Thus, in up-to-80-year-old hypertensive patients with left ventricular hypertrophy, age did not significantly attenuate hypertrophy reduction during antihypertensive treatment, although residual hypertrophy was more prevalent in older patients as a consequence of higher initial LV mass.
Nyckelord
- Age Factors
- Aged
- Aged
- 80 and over
- Antihypertensive Agents/*therapeutic use
- Atenolol/*therapeutic use
- Female
- Follow-Up Studies
- Heart Ventricles/ultrasonography
- Humans
- Hypertension/drug therapy
- Hypertrophy
- Left Ventricular/drug therapy/*ultrasonography
- Losartan/*therapeutic use
- Male
- Middle Aged
- Remission Induction
- Time Factors
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas